On 11 October 2011, the CRIMALDDI Consortium released their findings in a report “Malaria – a Roadmap for Drug Discovery”. In this report, they outlined the recommendations of this two-year project on the priorities for antimalarial drug discovery over the next five years.
What is CRIMALDDI?
CRIMALDDI stands for the Co-ordination, Rationalisation, and Integration of antiMALarial Drug Discovery & development Initiatives. It comprises a consortium of European and African antimalarial drug discovery & development centres that have come together to tackle a key challenge in the fight against malaria.
Antimalarial drug discovery and development globally is currently fragmented and uncoordinated. In order to meet the treatment objectives in the timescale of the Global Malaria Action Plan (GMAP), there is a need for the R&D being undertaken to be more co-ordinated and focused on key objectives. This will also help with establishing priorities for funding and resourcing. The CRIMALDDI Consortium has been set up by its members to develop and publicise an integrated and prioritised roadmap for antimalarial drug R&D to complement GMAP. The Consortium hopes that the roadmap and its associated 5-year action plan will function as a valuable planning tool for funding agencies and R&D organisations.
The members of the Consortium are:-
Liverpool School of Tropical Medicine
WHO / TDR
Medicines for Malaria Venture
University of Heidelberg
University of Milan
Centre National de la Recherché Scientifique
The Research Programme of INSERM
University of Cape Town
University of Buea